Global Cancer Peptide Drug Market Report 2026: Opportunities, Approved Drug Dosage, Price, Sales & Clinical Trials Insights to 2031
Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031" has been added to ResearchAndMarkets.com's offering.
The global cancer peptide drug market is projected to generate an opportunity exceeding USD 25 billion by 2031, supported by expanding oncology research, targeted drug development, radioligand programs and growing investment in peptide-based therapeutics. A new market intelligence report provides an in-depth assessment of approved cancer peptide drugs, clinical pipelines, commercial performance, pricing, dosage, patents, partnerships and emerging therapeutic opportunities.
Report Findings and Highlights
Expanding Role of Peptide Therapeutics in Cancer Treatment
The global cancer peptide therapeutics market has developed into an active and scientifically diverse area of oncology drug research. Peptide-based candidates are being investigated across receptor signaling pathways, intracellular protein interactions, tumor-targeted delivery, immune modulation and radiopharmaceutical applications. These capabilities are strengthening the role of peptides within next-generation targeted cancer treatment strategies.
The report evaluates the cancer peptide drug market through clinical development activity, strategic partnerships, licensing agreements, investment trends and emerging scientific platforms. It is designed to support pharmaceutical companies, biotechnology developers, investors and other oncology stakeholders in evaluating market opportunities and making informed development and commercialization decisions.
Cancer Peptide Clinical Trial Landscape
The report analyzes oncology peptide programs from first-in-human studies through advanced clinical development, registration studies and post-approval evaluation. The clinical pipeline spans common and rare cancer indications, highlighting the increasing application of peptide therapeutics across solid tumors and other malignancies.
Clinical trial coverage includes monotherapy and combination regimens, patient populations, treatment lines, routes of administration, study designs, sponsors, development partners and licensing arrangements. Available efficacy and safety findings are also assessed, including response rates, progression-free survival and overall survival outcomes. The analysis further examines the use of cancer peptide drugs with chemotherapy, immunotherapy and other antineoplastic treatments.
Companies Advancing Cancer Peptide Drug Research and Development
The cancer peptide therapeutics landscape includes multinational pharmaceutical companies and emerging biotechnology developers. Eli Lilly and Novartis are among the major companies participating in peptide-based oncology through licensing transactions, strategic partnerships and radioligand development programs. These initiatives position peptide technologies within broader oncology pipelines focused on targeted treatments and combination strategies.
Biotechnology companies, including Avacta Therapeutics and Gate2Brain, are also advancing peptide-based anticancer candidates through preclinical and clinical research. Collaboration between specialist biotechnology developers and established pharmaceutical organizations continues to support candidate translation, clinical validation and potential commercialization.
Future Cancer Peptide Therapeutics Market Opportunities
The report identifies several areas expected to influence future cancer peptide drug development. These include synthetic peptides targeting intracellular protein-protein interactions and oncogenic signaling pathways associated with tumor growth and survival. Research is also progressing in tumor penetration, targeted delivery, treatment selectivity and toxicity reduction.
Additional development opportunities include peptide-based immunotherapy, T-cell-focused approaches and peptide-guided delivery of radiopharmaceuticals to tumors. Venom-derived peptides are also assessed as a potential source of novel oncology candidates. Together, these advances demonstrate the broadening clinical and commercial potential of peptide therapeutics across the global cancer treatment market.
By combining market forecasts with detailed approved-drug and clinical-pipeline intelligence, the report provides a structured view of competitive positioning, product development, commercial performance and long-term opportunities in the global cancer peptide drug market through 2031.
Key Topics Covered
1. Introduction to Peptide Therapeutics
1.1 Overview Of Peptide Therapeutics
1.2 Classification Of Anticancer Peptides
1.3 Designing & Functioning of Peptide Drugs
1.4 Significance Of Peptides As Cancer Therapeutics
1.5 Role of Peptides in Cancer Immunotherapy
2. Different Approaches of Peptides in Cancer Therapeutics
2.1 Hormonal Peptides
2.2 Peptide Based Radionuclide Drug Carriers
2.3 Peptide Vaccines
2.4 Cytotoxic Drug Carriers
2.5 Anticancer Peptides
2.6 Tumor-Targeting and Cell-Penetrating Peptides
2.7 Peptide Nanomedicines
2.8 Receptor Antagonist and PPI-Modulating Peptides
2.9 Emerging Approaches
3. Global Cancer Peptide Drug Market Insight
3.1 Current Market Scenario
3.2 Future Market Opportunities
4. Cancer Peptide Research & Market Trends by Country
4.1 US
4.2 China
4.3 Europe
4.4 Canada
4.5 UK
4.6 Australia
4.7 Japan
4.8 South Korea
4.9 India
4.10 Middle East
4.11 Latin America
5. Cancer Peptide Research & Market Trends by Indication
5.1 Breast Cancer
5.2 Hematological Malignancies
5.3 Urothelial Cancer
5.4 Prostate Cancer
5.5 Lung Cancer
5.6 Skin Cancer
5.7 Gastrointestinal Cancer
5.8 Gynecological Cancer
5.9 CNS Cancers
6. Marketed Cancer Peptides Drugs & Generics Insight - Availability, Cost, Dosage, Indication & Patent Insight
6.1 Firmagon (Degarelix)
6.1 Eligard (Leuprolide)
6.2 Lupron (Leuprolide Acetate)
6.3 Gonax (Degarelix Acetate)
6.4 Trelstar (Triptorelin)
6.5 Decapeptyl/Decapeptyl DR (Treptorelin Acetate or Pamoate)
6.6 Velcade (Bortizomib)
6.7 Ninlaro (Ixazomib)
6.8 Kyprolis (Carfilzomib)
6.9 Istodax (Romidepsin)
6.10 Zoladex (Goserelin)
6.11 Cosmegen (Dactinomycin)
6.12 Somatuline Depot (Lanreotide)
6.13 Sandostatin/ Sandostatin LAR (Octreotide Acetate)
6.14 Bynfezia Pen (Octreotide)
6.15 Lutathera (Lutetium Lu 177 dotatate)
6.16 Mepact (Mifamurtide)
6.17 Netspot (Gallium Ga 68 dotatate)
6.18 Camcevi (Leuprolide)
7. Marketed Cancer Peptides Drugs Sales Insight
7.1 Kyprolis
7.2 Zoladex
7.3 Lutathera
7.4 Sandostatin
7.5 Somatuline
7.6 Decapeptyl SR
7.7 Ninlaro
7.8 Velcade
7.9 Lupron
8. Global Peptide Cancer Drugs Clinical Trials Insight by Company, Country, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase 0
8.4 Phase I
8.5 Phase I/II
8.6 Phase II
8.7 Phase II/III
8.8 Phase III
8.9 Preregistration
8.10 Registered
9. Marketed Peptide Cancer Drugs Clinical Insight by Company, Country & Indication
10. Venom Peptides: New Era For Cancer Peptide Therapy
10.1 Bee Venom-Derived Peptides
10.2 Scorpion Venom-Derived Peptides
10.3 Snake Venom-Derived Peptides
10.4 Spider Venom-Derived Peptides
10.5 Cone Snail Venom-Derived Peptides
11. Global Peptide Cancer Drug Market Dynamics
11.1 Favorable Market Parameters & Opportunities
11.2 Commercialization Challenges & Strategic Solutions
12. Therapeutic Peptide Targets
12.1 Signal Transduction Pathways
12.2 Cell Cycle Regulators
12.3 Apoptosis/Cell-Death Modulators
12.4 Tumor Suppressor Targeting peptides
12.5 Transcription Factor-Targeting Peptides
12.6 DNA Repair Pathway Inhibitors
12.7 Anti-Angiogenic Peptides
12.8 Immunomodulatory Peptides
12.9 Membrane-Disrupting/Oncolytic Peptides
13. Peptide Drugs vs Conventional Cancer Therapeutics
13.1 Peptide Therapeutics vs Chemotherapy
13.2 Peptide Therapeutics vs Immunotherapies
13.3 Peptide Therapeutics vs Gene Therapy
14. Competitive Landscape
14.1 3B Pharmaceuticals
14.2 APIM Therapeutics
14.3 AsclepiX Therapeutics
14.4 Bicycle Therapeutics
14.5 Biohaven Labs
14.6 BrightPath Biotherapeutics
14.7 Bristol-Myers Squibb
14.8 Gnubiotics Sciences
14.9 IDP Pharma
14.10 Janux Therapeutics
14.11 Medikine
14.12 Modulation Therapeutics
14.13 Novartis
14.14 Oncopeptides
14.15 Parabilis Medicines
14.16 PeptiDream
14.17 Perspective Therapeutics
14.18 Pharm-Sintez
14.19 Sapience Therapeutics
14.20 Vigeo Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/go9786
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.